The technology platform that Selecta Biosciences Inc. hopes will create new vaccines combines biodegradable polymers, formulated as nanoparticles, that can be processed in such a way that they “self-assemble” along with antigens and synthetic elements into complexes able to evoke clinically relevant immune responses. Selecta says its nanoparticles stimulate a human immune response similar to that roused by naturally occurring pathogens, perhaps because they are similar in size to a virus and because antigen is arrayed on the outside to optimally interact with the body’s B cells. On the inside, the nanoparticles contain what Selecta considers a “proprietary and universal” T-cell antigen intended to elicit a strong memory T-cell response. The interior of the company’s nanoparticles also contain a TLR, or Toll-like receptor, agonist meant to act as an adjuvant.
480 Arsenal Street
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now
A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.
Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.
Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.
Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now
South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.
Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.
